Esophageal adenocarcinoma carries a grave prognosis, with a relative 3-year survival rate of only 20% in the United States from 1995–1998 (Polednak 2003).

According to data from the Surveillance, Epidemiology, and End Results program (SEER) database, the incidence of esophageal carcinoma is rising more rapidly than any other form of cancer, with a six-fold increase from 1975 to 2001 (Devesa et al 1998Brown and Devesa 2002Pera et al 2005Pohl and Welch 2005).

As a predisposing condition to esophageal adenocarcinoma, gastro-esophageal reflux disease (GERD) is one of the most common medical conditions in the US..

The link between GERD and esophageal adenocarcinoma is Barrett’s esophagus (BE), a condition characterized by metaplastic changes in the esophageal epithelium.


Content 5


  • –Risk of adeno CA increases with gastroesophageal reflux disease (GERD) and high BMI (>30kg/m2)




Detection of Barrett’s esophagus allows for endoscopic surveillance in order to detect the potential development of dysplasia and early cancer before symptoms develop, and thereby significantly increases treatment options and may lower mortality from esophageal adenocarcinoma.

Barrett’s esophagus is present in 10%–20% of patients with gastroesophageal reflux disease (GERD) and has also been detected in patients who deny classic GERD symptoms and are undergoing endoscopy for other indications.

USMLE Reviewer

(By Subscription)